Polymyalgia rheumatica: A case series from Colombia and analysis of Latin America.
J Transl Autoimmun
; 4: 100115, 2021.
Article
em En
| MEDLINE
| ID: mdl-34485886
ABSTRACT
OBJECTIVE:
Polymyalgia rheumatica (PMR) is the most common inflammatory disease in patients over 50 years. Information about the disease in Latin America (LATAM) is scarce. We aimed to evaluate a group of Colombian patients with PMR and to conduct a systematic review of PMR in LATAM.METHODS:
A multicentric retrospective study was performed. Medical records of 256 PMR patients were evaluated. Patients were divided into two groups, those fulfilling the 2012 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for PMR and those who did not (i.e., clinical diagnosis). A systematic literature review and meta regression was performed comparing Colombian vs LATAM patients.RESULTS:
From 256 patients, 145 (56.6%) fulfilled the 2012 EULAR/ACR criteria, and 111 (43.3%) were classified by clinical diagnosis. Inflammatory bilateral shoulder pain, pelvic girdle aching, morning stiffness >45 min, elevated erythrocyte sedimentation rate (ESR), and C-reactive protein (CPR), and Methotrexate (MTX) prescription were more common in the 2012 EULAR/ACR group. None of the included patients presented overt polyautoimmunity (PolyA), whereas up to 24% exhibited latent PolyA. In addition, these patients showed high frequency of malignancy (7.59%). In the meta regression analysis, Colombian patients exhibited lower ESR levels, and were less likely to develop giant cell arteritis (GCA) as compared to the rest of LATAM data.CONCLUSION:
Patients with PMR in LATAM exhibit similar phenotypes from other cohorts worldwide. Malignancy, GCA and latent PolyA should be considered in the routine clinical follow-up of patients with PMR.
ACPA, Cyclic citrullinated peptide antibody.; ANAs, Antinuclear antibodies.; CART, Classification and regression trees.; CI, Confidence interval.; CRP, C-reactive protein.; DMARDs, Disease-modifying antirheumatic drugs.; ESR, Erythrocyte sedimentation rate.; EULAR/ACR, European League Against Rheumatism/American College of Rheumatology.; GCA, Giant cell arteritis; GCs, Glucocorticoids.; Giant cell arteritis; IQR, Interquartile range.; LATAM, Latin America.; Latin America; MTX, Methotrexate.; Neoplasms; OR, Odds ratio.; PMR, Polymyalgia rheumatica.; PRISMA, Preferred Reporting Items for Systematic Reviews and Metaanalyses.; PolyA, Polyautoimmunity.; Polyautoimmunity; Polymyalgia rheumatica; RF, Rheumatoid factor.; SD, Standard deviation.; Systematic review; ts-DMARDs, Targeted-synthetic disease-modifying antirheumatic drugs.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Clinical_trials
/
Observational_studies
/
Systematic_reviews
País/Região como assunto:
America do sul
/
Colombia
Idioma:
En
Revista:
J Transl Autoimmun
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Colômbia